Abstract
Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Current Pharmaceutical Design
Title: Lipid Management for the Prevention of Cardiovascular Disease
Volume: 17 Issue: 9
Author(s): Juergen R. Schaefer
Affiliation:
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Abstract: Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Export Options
About this article
Cite this article as:
R. Schaefer Juergen, Lipid Management for the Prevention of Cardiovascular Disease, Current Pharmaceutical Design 2011; 17 (9) . https://dx.doi.org/10.2174/138161211795428849
DOI https://dx.doi.org/10.2174/138161211795428849 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dysregulation of Glycogen Synthase Kinase-3 in Skeletal Muscle and the Etiology of Insulin Resistance and Type 2 Diabetes
Current Diabetes Reviews Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes
Current Drug Metabolism Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Coronary Calcium Risk Score and Cardiovascular Risk
Current Vascular Pharmacology Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Long-Term Exposure to Ambient Hydrocarbons Increases Dementia Risk in People Aged 50 Years and above in Taiwan
Current Alzheimer Research Functional Profiles of Human Umbilical Cord-Derived Adult Mesenchymal Stem Cells in Obese/Diabetic Versus Healthy Women
Current Diabetes Reviews Transient Tachypnea of the Newborn: The Treatment Strategies
Current Pharmaceutical Design Kidney in Diabetes: from Organ Damage Target to Therapeutic Target
Current Drug Metabolism Pseudomonas aeruginosa -Eukaryotic Cell Crosstalk: Mediators, Mechanisms and Implications for the Antimicrobial Therapy
Current Organic Chemistry Increased Salt Sensitivity in Obese Hypertension: Role of the Sympathetic Nervous System
Current Hypertension Reviews Selective Modulators of PPAR Activity as New Therapeutic Tools in Metabolic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of Hormonal Regulation of Sertoli Cell Development and Proliferation: A Key Process for Spermatogenesis
Current Molecular Pharmacology Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Genetics and Diabetic Retinopathy
Current Diabetes Reviews